Charles River Laboratories International, Inc. (NYSE: CRL) recently announced several key expansions to its global Biologics Testing Solutions infrastructure to support the characterization, development, and release of biologics and biosimilars. Growth in this industry has led to increased demand for outsourced services, providing an opportunity for Charles River to enhance capacity and capabilities in support of client needs.
To increase its capacity and support higher demand, Charles River recently added a new, 73,000 square-foot facility on Devon Park Road in Wayne, Pennsylvania. This facility will more than double the laboratory space available at Charles River’s existing facilities in Malvern and King of Prussia, Pennsylvania.
Certain laboratory operations conducted at Charles River’s Malvern and King of Prussia sites will begin to move to Devon Park early in the third quarter of 2018. The formal transfer of assays will be done in phases, and during the transition, both the Malvern and King of Prussia facilities will remain fully operational to ensure there will be no interruption of services.
Additional Capacity and Capability Enhancements
Approved Quotes
Caution Concerning Forward-Looking Statements
This press
release includes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by the use of words such as “anticipate,”
“believe,” “expect,” “intend,” “will,” “may,” “estimate,” “plan,”
“outlook,” and “project,” and other similar expressions that predict or
indicate future events or trends or that are not statements of
historical matters. Forward looking statements include statements in
this press release regarding future demand for drug discovery and
development products and services, the timing of the move of certain
laboratory operations to Charles River’s Devon Park site, the on-going
enhancements and expansions to our Malvern, Shrewsbury, Erkrath, and
Ballina sites, as well as the overall impact of these changes on the
Biologics Testing Solutions business. Forward-looking statements are
based on Charles River’s current expectations and beliefs, and involve a
number of risks and uncertainties that are difficult to predict and that
could cause actual results to differ materially from those stated or
implied by the forward-looking statements. A further description of
these risks, uncertainties, and other matters can be found in the Risk
Factors detailed in Charles River's Annual Report on Form 10-K as filed
on February 13, 2018, as well as other filings we make with
the Securities and Exchange Commission. Because forward-looking
statements involve risks and uncertainties, actual results and events
may differ materially from results and events currently expected by
Charles River, and Charles River assumes no obligation and expressly
disclaims any duty to update information contained in this news release
except as required by law.
About Charles River
Charles River provides essential
products and services to help pharmaceutical and biotechnology
companies, government agencies and leading academic institutions around
the globe accelerate their research and drug development efforts. Our
dedicated employees are focused on providing clients with exactly what
they need to improve and expedite the discovery, early-stage development
and safe manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180308005193/en/
Charles River Laboratories International, Inc.
Investor Contact:
Susan
E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
[email protected]
or
Media
Contact:
Amy Cianciaruso, 781-222-6168
Corporate Vice
President, Public Relations
[email protected]